Latest Conference Articles

For patients with diabetes controlling their condition is largely in their hands. How they work the process can determine their overall quality of life.

Alogliptin appears to slow the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus.

As the healthcare landscape has changed in recent years everyone from patients to doctors to pharmaceutical companies have had to change along with it.

The FDA rightfully cracked down on compounding pharmacies under a 2013 law brought on by 64 deaths traced to contaminated drugs at a dirty compounding facility. But physicians are concerned the FDA's new powers could end in-office compounding for individual patients, a common practice in many medical specialities.

The Congressional repeal of the Medicare sustained growth rate formula for calculating doctors' payments has the American Medical Association energized and ready to push for more reform. First up is trying to delay or stop the implementation of a new billing code system the group says will be costly for its members. It's known as ICD-10.

When blood glucose levels prove difficult to control in patients with type 2 diabetes mellitus, it may be time to consider adding a third drug to the treatment regimen.

With a complicated condition like diabetes there is more to treatment than finding the right medication for patients. Providing the information they need and direction to help in their daily lives is also a key part of the overall picture.

There are a substantial number of factors physicians must take into consideration before starting a patient with type 2 diabetes mellitus on a particular treatment path. According to results from a recent study, the effectiveness of one of the most popular diabetes medications may be dependent on a patient's race or ethnicity.

With multiple factors hurting patients' chances of reaching type 2 diabetes treatment goals – including a lack of timely follow-up appointments and yo-yo blood glucose (A1C) levels – a respected physician recently advised a major shift in treatment, especially early on in the progressive disease.

Even adults with diabetes may be injecting insulin incorrectly which could put them at higher risk for additional conditions, according to lead author Paula M. Trief, PhD, of SUNY Upstate Medical Center.

With more than 10000 people in Boston for the American Diabetes Association's Scientific Sessions the event provides a chance for some of the top minds in the field to share information.

With so many people affected by diabetes finding the right treatment for the individual patients is becoming a key factor in care.

Treatment of the relapsing form of multiple sclerosis has come a long way in recent years. The hope by researchers now is that treatment for progressive multiple sclerosis could be coming up sooner rather than later.

Pain levels due to diabetic peripheral neuropathy (DPN) may be altered depending on patients' vitamin D levels, a British study. The findings will be presented in a poster session on June 8 at the American Diabetes Association 75th Scientific Sessions in Boston, MA.

Generic drugs used to be the cheaper alternative to name brand drugs. Now they are sometimes more expensive. The blame could go to Wall Street, the Obama administration, or even pharma collusion, but someone better put a stop to the increases, AMA delegates agreed today.

DPP-4 inhibitors may also enhance beta cell function in patients with type 2 diabetes mellitus.

Diabetes researchers looked at the impact of chronic kidney disease on the glucose-regulating drug empagliflozin.

Results from a 104-week phase 3 study may have important implications for the way patients with type 2 diabetes mellitus tackle weight loss.

Insulin glargine, a commonly used treatment for type 2 diabetes mellitus, may be more effective when administered at a higher dose, according to results from a phase 3 study.

While medications go through extensive studies and research before being released to patients, the results in a controlled setting versus real-life situations may vary. Or do they?

Study results show that the combination of metformin and glibenclamide is as effective as insulin in achieving glycemic control in women with gestational diabetes and may be a more acceptable and cost effective therapy.

Researchers compared canagliflozin and sitagliptin treatment on HbA1c levels and body weight in patients with type 2 diabetes mellitus.

A rat study shows saxagliptin has promise for renal protection.

Empagliflozin, a diabetes drug that controls glucose levels, may also help ameliorate erectile dysfunction in patients with type 2 diabetes mellitus.

Approved by the US Food and Drug Administration (FDA) just over 4 years ago, linagliptin (Tradjenta) can help protect against renal injury in patients with type 2 diabetes.

Oxidative stress plays an important role in the ability for dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, to effectively ease diabetic nephropathy, according to lead author Takashi Hatanaka of Nagoya University. The study will be presented in a poster session on June 6 at the American Diabetes Association 75th Scientific Sessions in Boston, MA.

When treating elderly patients going under the knife may not always be the ideal solution to a problem. However, in some cases it may be the only option to ensuring a high quality of life for patients.

Changing the way medicine approaches a topic, especially a sensitive one like treating older patients is never easy. However, with more patients living well into their 70s and beyond it is becoming an increasingly important area of care.

Thanks to modern science people are living longer than they ever have before. While that is a positive in many ways it is also presenting new challenges to healthcare professionals in a variety of fields.

A growing trend in the medical community is the use of a technique known as mindfulness based stress reduction. While the results have shown to be inconclusive in the treatment of multiple sclerosis there is work being done to show its efficacy in helping patients.